Form 4: Vaxart Chief Medical Officer James F. Cummings Reports Stock Transaction

James F. Cummings, Chief Medical Officer of Vaxart, Inc., reports the withholding of 7,964 common stock shares to cover tax obligations related to vested RSUs on February 2, 2025.

Summary

• On February 4, 2025, James F. Cummings, the Chief Medical Officer of Vaxart, Inc., filed a Form 4 with the SEC.
• The report details a transaction on February 2, 2025, where 7,964 shares of common stock were withheld by Vaxart to satisfy income tax obligations related to the vesting of Restricted Stock Units (RSUs).
• The price per share for the transaction was $0.6798.
• Following the transaction, Cummings directly owns 318,837 shares of Vaxart common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard tax withholding related to RSU vesting, not indicative of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax withholding procedure related to the vesting of RSUs.

Key Dates

Keywords

Form 4, Vaxart, VXRT, James F. Cummings, Chief Medical Officer, Stock Transaction, Beneficial Ownership, Restricted Stock Units, RSUs, Tax Withholding